Back

Regeneron reports 73% response rate for ovarian cancer therapy

Verifying
  • Regeneron presented ubamatamab and trevogrumab clinical results at international medical meetings.
  • Ubamatamab produced a 73% objective response rate among patients receiving 800 mg monotherapy.
  • Regeneron plans further trials for both therapies, including a potentially registrational ubamatamab study.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Regeneron reports 73% response rate for ovarian cancer therapy - CoinPost Terminal